Organogenesis Holdings Inc (ORGO) stock surged 5.24% in after-hours trading on Thursday, outperforming the broader market. The regenerative medicine company's impressive growth prospects and strong insider confidence appear to be the key drivers behind this after-hours surge.

According to industry reports, ORGO is positioning itself as a leading player in the rapidly evolving regenerative medicine sector. The company reported improved fourth-quarter 2024 earnings, with sales reaching $126.66 million, up from $99.65 million in the prior year, and a net income of $7.67 million compared to a previous loss. While ORGO's revenue growth forecast is moderate at 9.2% annually, the company is expected to achieve profitability within three years, fueling investor optimism.

Notably, ORGO boasts a significant insider ownership of 37.6%, highlighting the management team's confidence in the company's future growth potential. With substantial investments in research and development aimed at driving innovation and maintaining a competitive edge, ORGO appears well-positioned to capitalize on the burgeoning demand for advanced regenerative medicine solutions, particularly in an aging population.